SecBot SecBot
SECBOTREPLAY Home › Report › PHIO

PHIO · Phio Pharmaceuticals is conducting an at-the-market offering of up to…

Phio Pharmaceuticals Corp. · 424B5 filed Apr 8, 2026 at 16:13 ET

At the news

NEUTRALIMPACT 5/10

424B5 filed Apr 8, 2026 at 16:13 ET

Phio Pharmaceuticals is conducting an at-the-market offering of up to $6.36 million in common stock through H.C. Wainwright & Co., with proceeds intended for advancing PH-762 into a Phase 2b/3 trial and general working capital. The offering follows a prior shelf registration and introduces potential near-term dilution.

  • Company is offering up to $6,360,000 in common stock through an at-the-market (ATM) offering with H.C. Wainwright & Co.
  • Proceeds will fund development of PH-762 in an expected Phase 2b/3 clinical trial for cutaneous squamous cell carcinoma, other development activities, and general working capital needs.
  • The offering is subject to a 3.0% commission paid to the sales agent.
  • As of December 31, 2025, there were 11,617,250 shares outstanding, with up to 16,586,000 shares to be outstanding after the offering.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access